Pfizer

Pfizer is an American, multinational pharmaceutical and biotechnology corporation. The company was founded in 1849, in New York, New York, United States.

Pfizer has the mission to fund programs that provide public benefit, advance medical care, and can improve patient outcomes. Their researchers preform 25,000 clinical tests everyday for pharmaceutical development and innovations.

Partnerships

BaseLaunch

Pfizer is a partner with the BaseLaunch startup accelerator. The BaseLaunch program receives applications in the fields of therapeutics, diagnostics, digital healthcare, healthcare services, therapeutic platforms, and medical technology.

Insilico Medicine

Insilico Medicine and Pfizer entered into a research collaboration agreement. The agreement allows Pfizer to utilize Insilico Medicine's machine learning technology and Pandomics Discovery Platform to research potential therapeutic targets for a variety of diseases.

AMRA Medical

AMRA Medical and Pfizer's partnership works to investigate body fat distribution and muscle composition in a range of diseases using the UK Biobank registry. The partnership involves the body composition analysis of 100,000 individuals.

CytoReason

Pfizer's partnership with CytoReason gives them access to CytoReason's machine learning platform for drug discovery and development.

XtalPi Inc.

XtalPi Inc. and Pfizer's research collaboration focuses on developing a hybrid physics-and artificial intelligence-powered software platform for accurate molecular modeling of small molecules. The platform is intended to advance both companies capabilities in drug design and solid-form selection.

Distributed Bio

Pfizer and Distributed Bio entered an agreement to license Distributed Bio's SuperHuman Platform to Pfizer. The SuperHuman 2.0 antibody discovery platform will allow Pfizer to utilize the antibody library for screening activities against Pfizer-selected targets.

Domain Therapeutics

Domain Therapeutics and Pfizer entered into a collaboration agreement to asses Domain Therapeutics's bioSensAll platform. The bioSensAll platform defines signaling signatures for each wild-type and mutant receptors. Pfizer aims to use the platform to assess the impact of mutations on different signaling pathways engaged by g protein-coupled receptors.

COVID-19

Pfizer announced that they have identified certain anti-viral compounds that are under development which could be effective in treating the novel coronavirus SARS-CoV-2 responsible for COVID-19. They may enter a partnership with a third party company to screen and identify potential compounds by the end of March, 2020 in order to begin testing in April, 2020.

Pfizer is partnered with BioNTech for co-development and distribution of an mRNA vaccine against SARS-CoV-2 called BNT162.

Timeline

May 4, 2021

Pfizer and BioNTech announces that they hope to file an emergency authorization request for their vaccine for children aged two to 11 in September in the United States.

May 2021

In a UK mix and match study published in the Lancet in May, 830 adults over 50 were randomised to get either the Pfizer or AstraZeneca vaccines first, then the other vaccine later.

April 21, 2021

The preliminary results of a report of 35,000 U.S. women who received either the Moderna or Pfizer shots while pregnant showed their rates of miscarriage, premature births and other complications were comparable to those observed in published reports on pregnant women before the pandemic.

February 25, 2021

Pfizer announces that it has begun studying a third dose of its Covid-19 vaccine, part of a strategy to guard against mutated versions of the coronavirus.

January 11, 2021

Today in healthcare news: EQRx has raised another $500 million, at least 50% of COVID-19 cases spread from people without symptoms, and some evidence that Pfizer's vaccine works against virus mutations.

2021

Pfizer reports its first-quarter 2021 revenues of $14.6 billion, a 42% operational growth.

The first-quarter revenues for the vaccine account for $3.5 billion of total revenues of $14.6 billion.

Although not explicitly addressed in the first-quarter announcement, the company expects the FDA to authorize the Pfizer-BioNTech COVID-19 vaccine within the week for adolescents ages 12 and older.

November 19, 2020

Pfizer and LianBio announce strategic collaboration to expand development of Novel Therapeutics in Greater China.

November 17, 2020

Pfizer launches Covid-19 vaccine delivery trial in four US states.

November 12, 2020

Commission approves contract with BioNTech-Pfizer alliance to ensure access to a potential vaccine

The European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses on behalf of all EU Member States, plus an option to request up to a further 100 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19. Member States can decide to donate the vaccine to lower and middle-income countries or to re-direct it to other European countries.

November 9, 2020

Pfizer announces that the COVID-19 vaccine it's been developing is 90% effective in people who are not known to already have had the virus.

Page 1 of 2

Products

Acquisitions

Patents

People

Name

Role

A. Santiesteban

Employee

Abby Michaud

Employee

Abdalrahman Mekky, CMA

Employee

Abinaya A

Employee

Abiola Joseph

Employee

Abraham Svinkelstin, PMP, MS, MS, CSSGB

Employee

Adam Escalante

Employee

Adekunle Adeniran

Employee

Agnes Lei

Employee

AHMET ADIYAMAN

Employee

Aimee Greene

Employee

Aindréas MacDomhnaill

Employee

Aine Aherne

Employee

Akanqsha Shetty

Employee

Alba Hernandez

Employee

Alec Robert Gilarde

Employee

Alejandra Fonseca

Employee

Alekhya Reddy

Employee

Alex Haddad

Employee

Alexander H. Buell

Employee

Alexandra Grossbarth

Employee

Alexey Chapyshev

Employee

Alican Liceoglu

Employee

Alisha Dhiman

Employee

Alison Hanlon

Employee

Page 1 of 28

...

Documentaries, videos and podcasts

Title

Date

Link

Companies

Company

CEO

Location

Products/Services

Pfizer

Alberta Bourla

New York, New York, United States

Medical, healthcare, biotechnology, and pharmaceutical products and services

News

Title

Author

Date

Publisher

Description

Pfizer says COVID-19 vaccine more than 90% effective in kids

By LAURAN NEERGAARD and MATTHEW PERRONE

October 22, 2021

AP NEWS

Pfizer says kid-size doses of its COVID-19 vaccine are safe and nearly 91% effective at preventing infections in elementary school children.Details of the study were posted online Friday as U.S.

EXPLAINER: Is it time to get a COVID-19 booster? Which one?

By LAURAN NEERGAARD and MIKE STOBBE

October 22, 2021

AP NEWS

Millions more Americans just became eligible for COVID-19 boosters but figuring out who's eligible and when can be confusing -- and adding to the challenge is that this time around, people can get a different type of vaccine for that extra dose.

Powell's age and cancer bout left him vulnerable to COVID

October 18, 2021

AP NEWS

Despite getting vaccinated against COVID-19, Colin Powell remained vulnerable to the virus because of his advanced age and history of cancer, highlighting the continued risk to many Americans until more of the population is immunized.

Why COVID boosters weren't tweaked to better match variants

By LAURAN NEERGAARD

October 18, 2021

AP NEWS

More COVID-19 booster shots may be on the way -- but when it's your turn, you'll get an extra dose of the original vaccine, not one updated to better match the extra-contagious delta variant.And that has some experts wondering if the booster campaign is a bit of a missed opportunity to target delta and its likely descendants.

The Latest: Court rejects challenge to Maine shot mandate

By The Associated Press

October 15, 2021

AP NEWS

PORTLAND, Maine -- A federal appeals court has denied an emergency request to stop a COVID-19 vaccine mandate from going into effect in Maine.The rule, announced by Democratic Gov. Janet Mills, requires health care workers to get vaccinated against the disease by Oct.

FDA panel takes up tough questions on J&J COVID-19 boosters

By MATTHEW PERRONE and LAURAN NEERGAARD

October 15, 2021

AP NEWS

WASHINGTON (AP) -- U.S. health advisers on Friday tackled who should get boosters of Johnson & Johnson's single-shot COVID-19 vaccine and when -- and whether using a competing brand for the second dose might provide better protection.

Next on FDA's agenda: Booster shots of Moderna, J&J vaccines

By LAURAN NEERGAARD and MATTHEW PERRONE

October 12, 2021

AP NEWS

WASHINGTON (AP) -- With many Americans who got Pfizer vaccinations already rolling up their sleeves for a booster shot, millions of others who received the Moderna or Johnson & Johnson vaccine wait anxiously to learn when it's their turn.

Pfizer, Bayer-backed Pyxis ups IPO price as biotech's public run continues unabated

Ben Adams

October 8, 2021

FierceBiotech

As a barometer of the rude health biotechs continue to find themselves in on Wall Street, Big Pharma-backed oncology player Pyxis Oncology is upping its IPO.

Pfizer asks US to allow COVID shots for kids ages 5 to 11

By LAURAN NEERGAARD and JENNIFER McDERMOTT

October 7, 2021

AP NEWS

Pfizer asked the U.S. government Thursday to allow use of its COVID-19 vaccine in children ages 5 to 11 in what would be a major expansion that could combat an alarming rise in serious infections in youngsters and help schools stay open.

What to expect as US weighs COVID shots for younger kids

By LAURAN NEERGAARD

October 7, 2021

AP NEWS

The Food and Drug Administration is considering whether to allow COVID-19 vaccinations in children ages 5 to 11 -- using kid-sized doses.Until now, only people 12 and older could be vaccinated in the U.S., with shots made by Pfizer and its partner BioNTech.

Pfizer's development leader becomes 2nd executive to retire in early 2022

Kyle LaHucik

October 6, 2021

FierceBiotech

Rod MacKenzie will leave Pfizer early next year after heading up clinical development and as the company seeks expanded use of its COVID-19 vaccine. The 35-year Pfizer veteran will retire around the same time as the Big Pharma's group president John Young.

Voyager Therapeutics looks to shake off a tough year as it pens Pfizer gene therapy pact worth $630M

Ben Adams

October 6, 2021

FierceBiotech

Hoping to make gene therapies safer and looking to move on from a troubled 18 months, Pfizer is putting down as much as $630 million in an upfront/milestone-based payment for Voyager's next-gen gene therapies.

EU regulator OKs Pfizer vaccine booster for 18 and older

October 4, 2021

AP NEWS

AMSTERDAM (AP) -- The European Union's drug regulator gave its backing Monday to administering booster shots of the Pfizer-BioNTech COVID-19 vaccine for people 18 and older.The European Medicines Agency said the booster doses "may be considered at least 6 months after the second dose for people aged 18 years and older."

COVID vaccines for teenagers: what UK parents need to know amid a new wave of misinformation

October 3, 2021

The Economic Times

Unfortunately, schools, parents and teenagers have also become the victims of anti-vaccination misinformation campaigns. For example, a fake vaccine consent form was recently sent to many UK schools in late September 2021. It reportedly arrived in an email disguised as being from the NHS, and a few schools believed it to be genuine and sent it to parents and guardians.

Pfizer tightens DMD patient criteria after serious adverse events crop up in phase 3 gene therapy trial

Annalee Armstrong

September 28, 2021

FierceBiotech

Pfizer is tightening up the criteria for Duchenne muscular dystrophy patients to participate in a phase 3 clinical trial for an experimental gene therapy after three serious adverse events were seen in ongoing studies.

The Latest: Pfizer tests COVID pill as preventive medicine

By The Associated Press

September 27, 2021

AP NEWS

NEW YORK -- Pfizer has started testing its potential COVID-19 treatment as a preventive medicine aimed at warding off the virus if a close contact gets it.The drugmaker said Monday that it will study the pill it is developing in combination with a low dose of the HIV drug ritonavir in people who are at least 18 years old and live in the same household with someone who is infected.

Pfizer tests oral COVID-19 antiviral for preventing infection in people living with patients

Annalee Armstrong

September 27, 2021

FierceBiotech

Looking to be the dominant player in COVID-19, Pfizer is kick-starting a phase 2/3 clinical trial for an oral therapeutic antiviral for adults who have been exposed to the coronavirus.

Pfizer stumbles close to finish line in growth hormone race, extending the lead of rival Ascendis

Nick Paul

September 27, 2021

FierceBiotech

Pfizer's bid to defend its growth hormone franchise against a new, more convenient competitor has hit a snag. The FDA has pushed back approval of Pfizer's once-weekly prospect, giving rival Ascendis Pharma a longer window in which to convert physicians and patients from current daily options without competition.

US has enough COVID-19 vaccines for boosters

September 26, 2021

The Economic Times

The spike in demand -- expected following last week's federal recommendation on booster shots -- would be the first significant jump in months. More than 70 million Americans remain unvaccinated despite the enticement of lottery prizes, free food or gifts and pleas from exhausted health care workers as the average number of deaths per day climbed to more than 1,900 in recent weeks.

US has enough COVID-19 vaccines for boosters, kids' shots

By TODD RICHMOND and KATHLEEN FOODY

September 26, 2021

AP NEWS

MADISON, Wis. (AP) -- With more than 40 million doses of coronavirus vaccines available, U.S. health authorities said they're confident there will be enough for both qualified older Americans seeking booster shots and the young children for whom initial vaccines are expected to be approved in the not-too-distant future.